Clinical trials: Severe Respiratory Infection
Convalescence, Corona Virus Infection
Convalescent Plasma Therapy in Patients With COVID-19
Scientists and medical workers all around the world were running out of time to manage COVID-19. Several studies have been done to understand the disease and ultimately to find possible treatment.
- Conditions
- Convalescence, Corona Virus Infection, Plaque
- Trial name
- NCT04407208
- Testing
- Convalescent plasma
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- Biofarma
Severe Acute Respiratory Syndrome, Coronavirus
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.
- Conditions
- Severe Acute Respiratory Syndrome, Coronavirus, SARS-CoV-2, COVID-19
- Trial name
- NCT04449276
- Testing
- CVnCoV Vaccine
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- CureVac
Severe Acute Respiratory Syndrome
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
OSCAR (Otilimab in Severe COVID-19 Related Disease) is a multi-center, double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of otilimab for the treatment of severe pulmonary COVID-19 related…
- Trial name
- OSCAR (NCT04376684)
- Testing
- Otilimab, Standard of care
- Where
- 120 sites in United States, Argentina and 17 more
- Volunteers
- 1,156 people
- Sponsor
- GlaxoSmithKline
COVID-19
Study of Efficacy of Different Treatment Regimens of Olokizumab
The primary objective of the study is to evaluate the efficacy and safety of Artlegia (INN: olokizumab) new dosing regimen in patients with moderate coronavirus infection (COVID-19) with signs of hyperinflammation.
- Trial name
- RESET (NCT05187793)
- Testing
- Olokizumab, Standard therapy
- Where
- 5 sites in Russia
- Volunteers
- 198 people
- Sponsor
- R-Pharm
CoronaVirus Disease-2019 (COVID-19)
Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection.
- Trial name
- NCT04644120
- Testing
- ABBV-47D11, ABBV-2B04
- Where
- 18 sites in United States, Hungary and 3 more
- Volunteers
- 25 people
- Sponsor
- AbbVie
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
A Study of TAK-019 in Healthy Japanese Adults (COVID-19)
TAK-019 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-019 can protect people from Covid-19 and to check for side effects from TAK-019.
- Trial name
- NCT04712110
- Testing
- TAK-019
- Where
- 2 sites in Japan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Takeda
COVID-19
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment.
- Trial name
- NCT05487040
- Testing
- PF-07321332 (nirmatrelvir)/ritonavir
- Where
- 52 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345…
- Conditions
- SARS-CoV-2, Influenza, RSV
- Trial name
- NCT05585632
- Testing
- mRNA-1010, mRNA-1345, mRNA-1273.214
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Pneumonitis, SARS-CoV Infection
GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infection
- Trial name
- NCT04590547
- Testing
- GLS-1027
- Where
- 17 sites in United States, Bulgaria and 3 more
- Volunteers
- 132 people
- Sponsor
- GeneOne Life Science, Inc.
Covid19
Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19
The objectives of the trial are to evaluate the efficacy and safety of trimodulin as add-on therapy to standard of care (SoC) compared to placebo treatment in adult hospitalized subjects with severe COVID-19.
- Trial name
- ESsCOVID (NCT04576728)
- Testing
- Trimodulin
- Where
- 17 sites in Brazil, France and 2 more
- Volunteers
- 166 people
- Sponsor
- Biotest
Community-acquired Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in hospitalized subjects with sCAP on invasive mechanical…
- Trial name
- ESsCAPE (NCT05722938)
- Testing
- Trimodulin
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 590 people
- Sponsor
- Biotest
Healthy Participant
A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults
A study to learn how the study medicine called Ibuzatrelvir is taken up into the blood in healthy Chinese adults.
- Trial name
- NCT07235137
- Testing
- Ibuzatrelvir
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Ethmoid Sinusitis
Sinopsys® Lacrimal Stent Indicated for Sinus Irrigation
The primary objective is to evaluate clinical data related to the safety and performance of the Sinopsys® Lacrimal Stent.
- Trial name
- NCT03304951
- Testing
- Sinopsys® Lacrimal Stent
- Where
- Czechia
- Volunteers
- 8 people
- Sponsor
- Sinopsys Surgical
Community-acquired Pneumonia
A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
A Phase 1b/2a, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma gelsolin (rhu-pGSN) Added to Standard of Care in Subjects…
- Trial name
- NCT03466073
- Testing
- Recombinant Human Plasma Gelsolin
- Where
- 8 sites in Australia, Georgia
- Volunteers
- 33 people
- Sponsor
- BioAegis Therapeutics Inc.
Coronavirus Infections, Severe Acute Respiratory Syndrome
Household Transmission Investigation Study for COVID-19 in Tropical Regions
This study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (SARS-CoV-2) or antibodies among individuals living in households where there is a confirmed…
- Conditions
- Coronavirus Infections, Severe Acute Respiratory Syndrome, SARS-CoV Infection
- Trial name
- EPI-COVID-19 (NCT04328129)
- Testing
- Human biological samples
- Where
- 4 sites in French Guiana, Guadeloupe and 1 more
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
COVID-19 Induced Pneumonia, Covid19
Asunercept in Patients With Severe COVID-19
This is an open-label, randomized, phase II study with the main objective to investigate the effectiveness and safety of an investigational drug (APG101; International Nonproprietary Name: asunercept) in patients with severe…
- Trial name
- ASUNCTIS (NCT04535674)
- Testing
- Asunercept
- Where
- 13 sites in Russia, Spain
- Volunteers
- 438 people
- Sponsor
- Apogenix AG
COVID-19
Specimen Collection Study From Coronavirus Disease 2019 (COVID-19) Vaccinated Adults and Adolescents
This is a specimen collection study intended to generate a biological specimen repository of samples from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults and adolescents ≥12 years old who will receive…
- Trial name
- CoVacSpec (NCT05252910)
- Where
- 32 sites in United States, Colombia and 5 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Pharm-Olam, LLC
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
The purpose of this study is to evaluate the efficacy, safety and tolerability of aclidinium bromide doses compared with placebo in the treatment of moderate to severe, stable chronic obstructive pulmonary disease.
- Trial name
- LAS-MD-38 (NCT01045161)
- Testing
- Aclidinium bromide
- Where
- 112 sites in United States, Canada
- Volunteers
- 544 people
- Sponsor
- AstraZeneca
Coronavirus, Covid19
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
The primary objective of this study is to evaluate the humoral immune response to CVnCoV in elderly adults aged ≥65 years and younger adults aged 18-45 years, 14 days after the second dose administration.
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04838847
- Testing
- CVnCoV Vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- CureVac
COVID-19 Infection
Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection
An Open-label, prospective, randomized, comparative, multiple doses applied in addition to the standard of care treatment of patients with moderate to severe COVID-19 infection
- Trial name
- NCT04374032
- Testing
- metenkefalin + tridecactide, The standard of care
- Where
- 5 sites in Bosnia and Herzegovina
- Volunteers
- 120 people
- Sponsor
- Bosnalijek D.D